PMID- 33238089
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231111
IS  - 2372-952X (Print)
IS  - 2372-952X (Electronic)
IS  - 2372-952X (Linking)
VI  - 8
IP  - 1
DP  - 2021 Jan
TI  - Exacerbations of Lung Disease in Alpha-1 Antitrypsin Deficiency.
PG  - 162-76
LID - 10.15326/jcopdf.2020.0173 [doi]
AB  - Alpha-1 antitrypsin deficiency (AATD) is an important risk factor for development 
      of chronic obstructive pulmonary disease (COPD). Patients with AATD classically 
      develop a different pattern of lung disease from those with usual COPD, decline 
      faster and exhibit a range of differences in pathogenesis, all of which may be 
      relevant to phenotype and/or impact of exacerbations. There are a number of 
      definitions of exacerbation, with the main features being worsening of symptoms 
      over at least 2 days, which may be associated with a change in treatment. In this 
      article we review the literature surrounding exacerbations in AATD, focusing, in 
      particular, on ways in which they may differ from such events in usual COPD, and 
      the potential impact on clinical management.
CI  - JCOPDF (c) 2021.
FAU - Smith, Daniel J
AU  - Smith DJ
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, 
      United Kingdom.
FAU - Ellis, Paul R
AU  - Ellis PR
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, 
      United Kingdom.
FAU - Turner, Alice M
AU  - Turner AM
AD  - Institute of Applied Health Research, University of Birmingham, Birmingham, 
      United Kingdom.
AD  - University Hospitals Birmingham, United Kingdom.
LA  - eng
GR  - British Lung Foundation/United Kingdom
GR  - Alpha-1 Foundation/United States
GR  - American Thoracic Society Foundation/United States
GR  - NIHR/United States
GR  - Health Foundation/United States
GR  - AstraZeneca/United States
GR  - CSL Behring/United States
GR  - Chiesi/United States
PT  - Journal Article
PL  - United States
TA  - Chronic Obstr Pulm Dis
JT  - Chronic obstructive pulmonary diseases (Miami, Fla.)
JID - 101635411
PMC - PMC8047608
OTO - NOTNLM
OT  - Alpha-1 antitrypsin deficiency
OT  - Chronic obstructive pulmonary disease
OT  - Emphysema
OT  - Exacerbation
OT  - Neutrophil
COIS- DJS and PRE have no conflicts of interest. AMT has received grants from 
      AstraZeneca, Chiesi Farmaceutici and CSL Behring.
EDAT- 2020/11/26 06:00
MHDA- 2020/11/26 06:01
PMCR- 2021/01/25
CRDT- 2020/11/25 17:26
PHST- 2020/11/26 06:00 [pubmed]
PHST- 2020/11/26 06:01 [medline]
PHST- 2020/11/25 17:26 [entrez]
PHST- 2021/01/25 00:00 [pmc-release]
AID - 10.15326/jcopdf.2020.0173 [doi]
PST - ppublish
SO  - Chronic Obstr Pulm Dis. 2021 Jan;8(1):162-76. doi: 10.15326/jcopdf.2020.0173.